View Item 

Show simple item record

Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients

dc.contributor.authorGossett, D. R.en_US
dc.contributor.authorAlo, P.en_US
dc.contributor.authorBristow, R. E.en_US
dc.contributor.authorGalati, M.en_US
dc.contributor.authorKyshtoobayeva, A.en_US
dc.contributor.authorFruehauf, J.en_US
dc.contributor.authorMontz, F. J.en_US
dc.date.accessioned2010-06-01T19:27:41Z
dc.date.available2010-06-01T19:27:41Z
dc.date.issued2004-01en_US
dc.identifier.citationGossett, D. R.; Alo, P.; Bristow, R. E.; Galati, M.; Kyshtoobayeva, A.; Fruehauf, J.; Montz, F. J. (2004). "Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients." International Journal of Gynecological Cancer 14(1): 145-151. <http://hdl.handle.net/2027.42/72601>en_US
dc.identifier.issn1048-891Xen_US
dc.identifier.issn1525-1438en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72601
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=14764043&dopt=citationen_US
dc.description.abstractGossett DR, Alo P, Bristow RE, Galati M, Kyshtoobayeva A, Fruehauf J, Montz FJ. Inability of immunohistochemistry to predict clinical outcomes of endometrial cancer patients. Introduction: Despite optimal surgery, some patients with early endometrial carcinoma develop recurrence and die of disease. A number of immunohistochemical (IHC)-identified cell products (markers) have been proposed as predictors of recurrence. This study characterizes a large series of endometrial carcinomas with previously described markers as well as markers that have not been investigated in endometrial carcinoma. Patients and methods: Women who had undergone surgery for endometrial carcinoma were identified and specimens accessed. Tissue blocks were evaluated for ten IHC markers. Results were correlated with last known clinical status. Results: Mean follow-up was 43 months; complete data were available on 117 patients. Two women died of other causes; of the remaining 115, eight died of disease and six were alive with recurrence at last follow-up (12%). Vascular endothelial growth factor staining independently predicted recurrence and death. However, in multivariate analyses, only FIGO stage predicted outcome. Discussion: Our goal was to identify markers to predict which women with endometrial carcinoma were likely to have disease recurrence. We evaluated cell-cycle regulatory proteins, growth factors, hormone receptors, and angiogenic factors, but did not identify any marker that independently predicted outcome in multivariate analysis. This may reflect the few negative outcomes in our population.en_US
dc.format.extent302103 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Incen_US
dc.rightsIGCS, 2004en_US
dc.subject.otherEndometrial Canceren_US
dc.subject.otherImmunohistochemistryen_US
dc.subject.otherVEGFen_US
dc.titleInability of immunohistochemistry to predict clinical outcomes of endometrial cancer patientsen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelObstetrics and Gynecologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationum* The University of Michigan Medical Center, Department of Gynecologic Oncology, Ann Arbor, MI;en_US
dc.contributor.affiliationother† University of Rome, Department of Anatomic Pathology, Rome, Italy;en_US
dc.contributor.affiliationother† The Johns Hopkins Hospital and Medical Institutions, Kelly Gynecologic Oncology Service, Baltimore, MD;en_US
dc.contributor.affiliationother§ University of Rome, Department of Gynecology, Rome, Italy;en_US
dc.contributor.affiliationother¶ Oncotech, Inc., Tustin, CAen_US
dc.identifier.pmid14764043en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72601/1/j.1048-891x.2004.014028.x.pdf
dc.identifier.doi10.1111/j.1048-891x.2004.014028.xen_US
dc.identifier.sourceInternational Journal of Gynecological Canceren_US
dc.identifier.citedreference 1  American Cancer Society. Cancer Facts and Figures 2002, Atlanta GA: American Cancer Society; 2002.en_US
dc.identifier.citedreferenceBurris H. Docetaxel (taxotere) plus trastuzumab (Herceptin) in breast cancer. Semin Oncol 2001; 28 ( s3 ): 38 – 44.en_US
dc.identifier.citedreferenceHortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001; 28 ( 6 S18 ): 43 – 7.en_US
dc.identifier.citedreferenceGehrig PA, Van Le L, Olatidoye B, Geradts J. Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma. Cancer 1999; 86: 2083 – 9.en_US
dc.identifier.citedreferenceSivridis E, Giatromanolaki A, Koukourakis M, Anastasiadis P. Endometrial carcinoma: association of steroid hormone receptor expression with low angiogenesis and bcl-2 expression. Virchow's Arch 2001; 438: 470 – 7.en_US
dc.identifier.citedreferenceDeligdisch L, Kase N, Bleiweiss I. Endometrial cancer in elderly women: a histologic and steroid receptor analysis. Gerontology 2000; 46: 17 – 21.en_US
dc.identifier.citedreferenceKhalifa M, Mannel R, Haraway S, Walker J, Min K. Expression of EGF-R, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53: 84 – 92.en_US
dc.identifier.citedreferenceHirai M, Nakagawara A, Oosaki T, Hayashi Y, Horon M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001; 80: 181 – 8.en_US
dc.identifier.citedreferenceSeki N, Kodama J, Hongo A, Miyagi Y, Yoshinouchi M, Kudo T. Vascular endothelial growth factor and platelet-derived endothelial growth factor expression are implicated in the angiogenesis of endometrial cancer. Eur J Cancer 2000; 36: 68 – 73.en_US
dc.identifier.citedreferenceFine BA, Valente PT, Feinstein GI, Dey T. VEGF, flt-1, and KDR/flk-1 as prognostic indicator in endometrial carcinoma. Gyn Oncol 2000; 76: 33 – 9.en_US
dc.identifier.citedreferenceMiturski R, Semczuk A, Postawski K, Jakowicki J. Epidermal growth factor receptor immunostaining and epidermal growth factor receptor-tyrosine kinase activity in proliferative and neoplastic human endometrium. Tumor Biol 2000; 21: 358 – 66.en_US
dc.identifier.citedreferenceGiatromanolaki A, Sivridis E, Koukourakis M, Harris A, Gatter K. Bcl-2 and p53 expression in stage I endometrial carcinoma. Anticancer Res 1998; 18: 3689 – 94.en_US
dc.identifier.citedreferenceÖzsaran A, TÜrker S, Dikmen Y et al. p53 staining as a prognostic indicator in endometrial carcinoma. Eur J Gynaec Oncol 1999; 20: 156 – 9.en_US
dc.identifier.citedreferenceRamondetta L, Palazzo J, Dunton C, Kovatich A, Carlson J. A comparative analysis of Ki-67, p53, and p21 waf1cip1 expression in tamoxifen associated endometrial carcinomas. Anticancer Res 1998; 18: 4661 – 6.en_US
dc.identifier.citedreferenceCoppola D, Fu L, Nicosia S, Kounelis S, Jones M. Prognostic significance of p53, bcl-2, vimentin and S100 protein-positive langerhans cells in endometrial carcinoma. Hum Pathol 1998; 29: 455 – 62.en_US
dc.identifier.citedreferenceSeki N, Kodama J, Hashimoto I, Hongo A, Yoshinouchi M, Kudo T. Thrombospondin-1 and -2 messenger RNA expression in normal and neoplastic endometrial tissues: correlation with angiogenesis and prognosis. Int J Oncol 2001; 19: 305 – 10.en_US
dc.identifier.citedreferenceWang SC. Targeting HER2: recent developments and future directions for breast cancer patients. Semin Oncol 2001; 28 ( 6 S18 ): 21 – 9.en_US
dc.identifier.citedreferenceEmi Y. Metastatic breast cancer with HER2/neu positive cells tends to have a morbid prognosis. Surgery 2002; 131: S217 – 21.en_US
dc.identifier.citedreferenceMirza AN. Prognostic factors in node-negative breast cancer: a review of studies with sample size more than 200 and follow up more than 5 years. Ann Surg 2002; 235: 10 – 26.en_US
dc.identifier.citedreferenceMeden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstetr Gynecol Reprod Biol 1997; 71: 173 – 9.en_US
dc.identifier.citedreferenceSapino A, Bongiovanni M, Cassoni P et al. Expression of CD31 by cells of extensive ductal in situ and invasive carcinomas of the breast. J Pathol 2001; 194: 254 – 61.en_US
dc.identifier.citedreferenceKumar S, Ghellal A, Li C et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59: 856 – 61.en_US
dc.identifier.citedreferenceLi C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor β and CD105. Microsc Res Tech 2001; 52: 437 – 49.en_US
dc.identifier.citedreferenceAlbo D, Rothman V, Roberts D, Tuszynski G. Tumour cell thrombospondin-1 regulates tumour cell adhesion and invasion through the urokinase plasminogen activator receptor. Br J Cancer 2000; 83: 298 – 306.en_US
dc.identifier.citedreferenceDiSaia PJ, Creasman WT. Adenocarcinoma of the uterus. In: DiSaia, PJ, Creasman, WT, eds. Clinical Gynecologic Oncology, 6th edn. St. Louis, MO: Mosby-Year Book, Inc. 2002, 137 – 71.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1048-891x.2004.014028.x.pdf
Size:
295.0KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.